Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Licenses Gene Silencing IP from Plant Bioscience Limited

Premium

Dicerna Pharmaceuticals announced this week that it has taken a non-exclusive license to RNAi intellectual property held by Plant Bioscience Limited.

The IP includes US patent No. 8,097,710, as well as three related patents, which broadly cover the use of small RNAs to trigger post-transcriptional gene silencing and are based on the pioneering plant work of Sainsbury Laboratory researchers David Baulcombe and Andrew Hamilton.

In early 2012, a PBL official told Gene Silencing News that the organization aims to make the IP as widely available as possible.

Under the deal with PBL, Dicerna will have the rights to use the patented technology for human therapeutics. Financial terms of the arrangement were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.